Identification of pyrimidine derivatives as hSMG-1 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 21, 2012, Pages 6636-6641

  Gopalsamy, Ariamala ^a   Bennett, Eric M ^a   Shi, Mengxiao ^a   Zhang, Wei Guo ^a   Bard, Joel ^a   Yu, Ker ^a  

^a PFIZER INC   (United States)

Author keywords

hSMG 1 inhibitor; mTOR; Pyrimidine

Indexed keywords

CYCLIN DEPENDENT KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PYRIMIDINE DERIVATIVE;

ARTICLE; CHEMICAL ANALYSIS; DRUG IDENTIFICATION; DRUG SCREENING; DRUG SELECTIVITY; STRUCTURE ACTIVITY RELATION;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIMIDINES;

EID: 84867573846     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.08.107     Document Type: Article

References (33)

1. C.A. Lovejoy, and D. Cortez DNA Repair (Amst.) 8 2009 1004
2. S.J. Shuttleworth, F.A. Silva, A.R. Cecil, C.D. Tomassi, T.J. Hill, F.I. Raynaud, P.A. Clarke, and P. Workman Curr. Med. Chem. 18 2011 2686
3. P. Baumann, L. Schneider, S. Mandl-Weber, F. Oduncu, and R. Schmidmaier Anticancer Drugs 23 2012 131
4. G. Prasad, T. Sottero, X. Yang, S. Mueller, C.D. James, W.A. Weiss, M.Y. Polley, T. Ozawa, M.S. Berger, D.T. Aftab, M.D. Prados, and D.A. Haas-Kogan Neuro. Oncol. 13 2011 384
5. B.K. Law Crit. Rev. Oncol. Hematol. 56 2005 47
6. M.H. Voss, A.M. Molina, and R.J. Motzer Hematol. Oncol. Clin. North Am. 25 2011 835
7. J. Zhang, T.M. Roberts, and R.A. Shivdasani Gastroenterology 141 2011 50
8. A. Zask, J. Kaplan, J.C. Verheijen, D.J. Richard, K. Curran, N. Brooijmans, E.M. Bennett, L. Toral-Barza, I. Hollander, S. Ayral-Kaloustian, and K. Yu J. Med. Chem. 52 2009 7942
9. A. Zask, J.C. Verheijen, K. Curran, J. Kaplan, D.J. Richard, P. Nowak, D.J. Malwitz, N. Brooijmans, J. Bard, K. Svenson, J. Lucas, L. Toral-Barza, W.G. Zhang, I. Hollander, J.J. Gibbons, R.T. Abraham, S. Ayral-Kaloustian, T.S. Mansour, and K. Yu J. Med. Chem. 52 2009 5013
10. A. Zask, J.C. Verheijen, D.J. Richard, J. Kaplan, K. Curran, L. Toral-Barza, J. Lucas, I. Hollander, and K. Yu Bioorg. Med. Chem. Lett. 20 2010 2644
11. Y. Li, and D.Q. Yang Mol. Cancer Ther. 9 2010 113
12. D. Davidson, Y. Coulombe, V.L. Martinez-Marignac, L. Amrein, J. Grenier, K. Hodkinson, J.Y. Masson, R. Aloyz, and L. Panasci Invest. New Drugs. 30 3 2012 1248 1256 Jun
13. G. Denning, L. Jamieson, L.E. Maquat, E.A. Thompson, and A.P. Fields J. Biol. Chem. 276 2001 22709
14. R. Pulak, and P. Anderson Genes Dev. 1993 1885 7
15. R.T. Abraham DNA Repair (Amst.) 3 2004 919
16. A. Yamashita, I. Kashima, and S. Ohno Biochim. Biophys. Acta 1754 2005 305
17. F. Usuki, A. Yamashita, I. Kashima, I. Higuchi, M. Osame, and S. Ohno Mol. Ther. 14 2006 351
18. J.A. Holbrook, G. Neu-Yilik, M.W. Hentze, and A.E. Kulozik Nat. Genet. 36 2004 801
19. A.L. Atkin, L.R. Schenkman, M. Eastham, J.N. Dahlseid, M.J. Lelivelt, and M.R. Culbertson J. Biol. Chem. 272 1997 22163
20. C.M. Azzalin, and J. Lingner Curr. Biol. 16 2006 433
21. L.B. Gardner Mol. Cancer Res. 8 2010 295
22. K.M. Brumbaugh, D.M. Otterness, C. Geisen, V. Oliveira, J. Brognard, X. Li, F. Lejeune, R.S. Tibbetts, L.E. Maquat, and R.T. Abraham Mol. Cell 14 2004 585
23. E. Gubanova, B. Brown, S.V. Ivanov, T. Helleday, G.B. Mills, W.G. Yarbrough, and N. Issaeva Clin. Cancer Res. 18 2012 1257
24. F. Meslin, A. Hamai, B. Mlecnik, F. Rosselli, C. Richon, A. Jalil, G. Wemhoff, J. Thiery, J. Galon, and S.J. Chouaib Mol. Med. (Berl.) 89 2011 411
25. J.S. Gewandter, R.A. Bambara, and M.A. O'Reilly Cell Cycle 10 2011 2561
26. Gopalsamy, A.; Shi, M.; Bennett, E. M.; Zask, A.; Curran, K. J.; Venkatesan, A. M. International patent publication WO 2010/120991 A1, 2010.
27. K. Yu, and L. Toral-Barza Methods Mol. Biol. 2012 821
28. H.V. Namboodiri, M. Bukhtiyarova, J. Ramcharan, M. Karpusas, Y. Lee, and E.B. Springman Biochemistry 49 2010 3611
29. M.A. Seeliger, B. Nagar, F. Frank, X. Cao, M.N. Henderson, and J. Kuriyan Structure 15 2007 299
30. M. Anderson, J.F. Beattie, G.A. Breault, J. Breed, K.F. Byth, J.D. Culshaw, R.P. Ellston, S. Green, C.A. Minshull, R.A. Norman, R.A. Pauptit, J. Stanway, A.P. Thomas, and P.J. Jewsbury Bioorg. Med. Chem. Lett. 13 2003 3021
31. Homology modeling methods: hSMG-1 models were constructed using modeller (Eswar, N.; Marti-Renom, M. A.; Webb, B.; Madhusudhan, M. S.; Eramian, D.; Shen, M.; Pieper, U.; Sali, A. Curr. Protocols Bioinform. Suppl. 2006, 15, 5.6.1) with various PI3K structures as templates. Active site side chain positions were then reoptimized in the presence of an aminopyrimidine inhibitor using MacroModel with protocols similar to those described for docking. Initial models used unpublished PI3K-γ crystal structures from the same inhibitor series as PDB entry 3IBE. After solving 4FUL, models were rebuilt using 4FUL and 2RD0 as templates, and these models gave better results (tighter conformer clusters closer to the position observed for 2 bound to PI3K), possibly due to adjustments in the hinge and C-helix between 3IBE and 4FUL. Relative to PI3K-γ, hSMG-1 contains a ∼60-residue insertion in the kinase domain. The models did not include this region, but covered 220 residues of the kinase domain, of which 14 were judged insertions in hSMG-1 relative to PI3K-γ, 49 were conserved, and the remainder differed.
32. X.J. Chu, W. DePinto, D. Bartkovitz, S.S. So, B.T. Vu, K. Packman, C. Lukacs, Q. Ding, N. Jiang, K. Wang, P. Goelzer, X. Yin, M.A. Smith, B.X. Higgins, Y. Chen, Q. Xiang, J. Moliterni, G. Kaplan, B. Graves, A. Lovey, and N. Fotouhi J. Med. Chem. 49 2006 6549
33. D.J. Pratt, J. Bentley, P. Jewsbury, F.T. Boyle, J.A. Endicott, and M.E. Noble J. Med. Chem. 49 2006 5470